SCHEMBL1108713

SCHEMBL1108713

Cn1c(C2(c3ccccc3)CC2)nnc1[C@H]1CC[C@H](Oc2ccc(Cl)cc2Cl)CC1

nearest known ligand 0.45

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 16/20 0.45
NR1I2 O75469 6/20 0.43
FPR2 P25090 4/20 0.39
PROKR1 Q8TCW9 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13436624 0.85 HSD11B1 (0.41) HSD11B1NR1I2
SCHEMBL1108898 0.83 HSD11B1 (0.43) HSD11B1NR1I2FPR2PROKR1
SCHEMBL1108710 0.78 MEN1 (0.49) HSD11B1NR1I2
SCHEMBL1108790 0.75 HSD11B1 (0.46) HSD11B1NR1I2
SCHEMBL1108861 0.74 SCD (0.43) HSD11B1NR1I2
SCHEMBL3555315 0.73 HSD11B1 (0.52) HSD11B1NR1I2
SCHEMBL1108854 0.73 SCD (0.50) HSD11B1NR1I2
SCHEMBL1108714 0.73 MEN1 (0.45) HSD11B1NR1I2
SCHEMBL1108798 0.73 HSD17B10 (0.41) HSD11B1NR1I2
SCHEMBL1108796 0.72 ALDH1A1 (0.43) HSD11B1NR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153631-B2 Triazole compounds and uses related thereto AMGEN INC. (US) 2012-04-10 US disclosed
US-8153631-B2 Triazole compounds and uses related thereto AMGEN INC. (US) 2012-04-10 US disclosed
US-20100062972-A1 TRIAZOLE COMPOUNDS AND USES RELATED THERETO AMGEN INC. 2010-03-11 US disclosed
US-20100062972-A1 TRIAZOLE COMPOUNDS AND USES RELATED THERETO AMGEN INC. 2010-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100062972-A1 TRIAZOLE COMPOUNDS AND USES RELATED THERETO HSD11B1, HSD17B1, HSD17B3 HSD11B1 1/4885NR1I2 211/4885FPR2 4160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.